皮质警示素:治疗慢性呼吸道疾病的新目标
Denislava Nedeva1, Krzysztof Kowal2, Stefan Mihaicuta3,4
1Clinic of Asthma and Allergology, UMBAL Alexandrovska, Medical University Sofia, Sofia, Bulgaria.
像TSLP和IL-33这样的警示剂在慢性呼吸系统疾病中启动免疫反应. 针对这些警示素的治疗方法对严重喘和慢性肺炎有前途,需要进一步研究.
科学领域:
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 上皮细胞在受伤时释放警示素 (TSLP,HMGB1,IL-33,IL-25),从而启动先天免疫反应.
- 这些警示素与T2免疫反应,喘,气道重塑和肺纤维化有关,使它们成为慢性呼吸道疾病 (CRD) 的治疗点.
研究的目的:
- 审查TSLP,IL-33,IL-25和HMGB1在喘,COPD,异常性肺纤维化和囊性纤维化病原发生症中的作用.
- 总结关于CRD抗警疗法的证据.
主要方法:
- 关于CRD病变发生中的警示素作用的已发表数据的文献综述.
- 临床试验证据的总结,用于CRD中的抗警疗法.
主要成果:
- 反TSLP和IL-33/R抗体在严重喘临床试验中改善了结果.
- 阻断IL-33可减少COPD患者,特别是前吸烟者的恶化.
结论:
- 警示路径 (IL-33,TSLP) 是严重喘和COPD的有希望的治疗点.
- 需要进一步的研究来充分阐明警示机制,并确定它们在CRD治疗策略中的作用.
更多相关视频
14:48Flow Cytometric Isolation of Primary Murine Type II Alveolar Epithelial Cells for Functional and Molecular Studies
Published on: December 26, 2012
09:27Multicellular Human Alveolar Model Composed of Epithelial Cells and Primary Immune Cells for Hazard Assessment
Published on: May 6, 2020
相关概念视频
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Breathing
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
